Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy
Milind Y. Desai, Kathy Wolski, Anjali Owens, Srihari S. Naidu, Jeffrey B. Geske, Nicholas G. Smedira, Hartzell V. Schaff, Kathy Lampl, Ellen McErlean, Christina Sewell, David Zhang, Jay M. Edelberg, Amy J. Sehnert, Steven E. Nissen
Topics & Concepts
MedicineHypertrophic cardiomyopathyClinical endpointPlaceboInternal medicineCardiologyGuidelineSurrogate endpointPopulationCardiomyopathyVentricular outflow tract obstructionClinical trialRandomized controlled trialPhysical therapyHeart failurePathologyAlternative medicineEnvironmental healthCardiomyopathy and Myosin StudiesCardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling